Study Title
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S)
SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients with
COVID-19 (Regeneron 2067)
Purpose
This research study is looking at treatment with Regeneron Monoclonal Antibody Treatment for Covid-19 positive expectant mothers and children. The study drug targets the virus that causes COVID-19 and may make it harder for the virus to infect you further. The goals of the study include seeing whether the drug reduces the need for medical visits. ALL QUALIFIED PATIENTS RECEIVE REGENERON MONOCLONAL ANTIBODY TREATMENT.
Eligibility
Study Process
Trial Details
Investigator:
Joseph Bocchini, M.D.
IRB:
WIRB
IRB Number:
Trial Type:
Drug
Sponsor:
Regeneron
Contact Information: